Fast and safe : Optimising multiple sclerosis infusions during COVID-19 pandemic
Rath, Louise, Bui, Minh Viet, Ellis, Julian, Carey, John, Baker, Josephine, Taylor, Lisa, Fernando, Hasini, Taylor, Nicola, Savage, Poppy, Richards, Janene, Zhong, Michael, Kalincik, Tomas, Skibina, Olga, Wesselingh, Robb, Nguyen, Ai-Lan, Monif, Mastura, Butzkueven, Helmut and van der Walt, Anneke. (2021). Fast and safe : Optimising multiple sclerosis infusions during COVID-19 pandemic. Multiple Sclerosis and Related Disorders. 47, p. Article 102642. https://doi.org/10.1016/j.msard.2020.102642
|Authors||Rath, Louise, Bui, Minh Viet, Ellis, Julian, Carey, John, Baker, Josephine, Taylor, Lisa, Fernando, Hasini, Taylor, Nicola, Savage, Poppy, Richards, Janene, Zhong, Michael, Kalincik, Tomas, Skibina, Olga, Wesselingh, Robb, Nguyen, Ai-Lan, Monif, Mastura, Butzkueven, Helmut and van der Walt, Anneke|
Background: The COVID-19 pandemic challenges multiple sclerosis services to be innovative in delivering infusible therapies. To reduce time in clinical settings, and potential staff or space losses, we implemented rapid infusion protocols for selected patients.
Objective: To analyse the rate of infusion related reactions and patient experience of rapid infusions of natalizumab and ocrelizumab. To document time reduction patients spent in clinical settings during the COVID-19 pandemic.
Methods: Patients with prior exposure to at least three natalizumab or two 300mg ocrelizumab infusions were approved for rapid protocols. A retrospective audit and survey were completed.
Results: We analysed 269 rapid natalizumab infusions and 100 rapid ocrelizumab infusions. Infusion related reactions during the natalizumab or ocrelizumab infusions occurred in two patients (1.52%) and eight patients (8%), respectively. All infusion related reactions were mild to moderate and did not require infusion discontinuation. No infusion reactions occurred during the post-infusion observation. Patient experience was positive.
Conclusion: Frequency or severity of infusion related reactions in rapid infusions were no different compared to published data. In the setting of COVID-19, pandemic rapid infusion protocols could potentially save hospital resources and limit patient exposure to a high-risk clinical setting while still maintaining ongoing treatment of multiple sclerosis.
|Keywords||multiple sclerosis; COVID-19 pandemic; resource utilisation; infusion related reactions; rapid infusions; natalizumab; ocrelizumab; post observational time|
|Journal||Multiple Sclerosis and Related Disorders|
|Journal citation||47, p. Article 102642|
|Digital Object Identifier (DOI)||https://doi.org/10.1016/j.msard.2020.102642|
All rights reserved
File Access Level
|Online||01 Dec 2020|
|Publication process dates|
|Accepted||22 Nov 2020|
|Deposited||01 Dec 2022|
1views this month
0downloads this month